Canada Markets closed

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4000-0.0100 (-0.71%)
At close: 04:00PM EST
1.4000 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.4100
Open1.3800
Bid1.3600 x 800
Ask1.4500 x 1000
Day's Range1.3800 - 1.4216
52 Week Range1.2600 - 6.4800
Volume113,287
Avg. Volume114,006
Market Cap38.677M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-1.3290
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.33
  • GlobeNewswire

    NextCure to Present at Upcoming Investor Conferences

    BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences: Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 3:30 pm (ET) in New York City JMP Securities Hematology and Oncology Summit (Virtual) on

  • GlobeNewswire

    NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

    BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology. Under the terms of the agreement, both parties will equally share the costs to develop the

  • GlobeNewswire

    NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

    BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 cl